Array BioPharma To Report Financial Results For The First Quarter Of Fiscal 2013 On October 29, 2012

BOULDER, Colo., Oct. 23, 2012 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:  ARRY) will report financial results for the first quarter of fiscal 2013 on Monday, October 29, 2012, and will hold a conference call on Tuesday, October 30, 2012 at 9:00 a.m. eastern time to discuss these results.  Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.

Conference Call Information


Tuesday, October 30, 2012


9:00 a.m. eastern time





Pass Code:


Webcast & Conference Call Slides:


A replay of the call will be available as a webcast on

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small‑molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly‑owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune / Roche), having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013.  For more information on Array, please go to

SOURCE Array BioPharma Inc.


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.


PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.